Finding new treatments for schistosomiasis infections
Official title: Discovery and development of novel schistosomicidal agents
Funded at Acheminall Corporation · NIH-10921896 · Data updated 2026-11-12
This study is working on finding new medicines to help treat schistosomiasis, a disease caused by parasitic worms, by targeting a key enzyme that the worms need to survive, with the goal of creating better treatments than the current option.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Acheminall Corporation NIH-funded |
| Lab location | 1 site (Naperville, United States) |
| Project start | June 21, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 1R41AI184237-01 |
| Project ID | NIH-10921896 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals infected with schistosomiasis, particularly those who may not respond well to existing treatments.
✕Less likely to help
Patients who are not infected with schistosomiasis or those who have already been effectively treated with current medications may not benefit from this research.
What this research studies
This research focuses on developing new drugs to treat schistosomiasis, a disease caused by parasitic worms that affects millions worldwide. The team is investigating a specific enzyme in the worms that is crucial for their survival, aiming to create drugs that can effectively target and inhibit this enzyme. By screening large libraries of compounds, they hope to identify new treatments that can overcome the limitations of the current medication, praziquantel, especially against juvenile worms. The research involves biochemical assays and high-throughput screening to discover and optimize potential drug candidates.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective new treatments for schistosomiasis, improving health outcomes for millions of affected individuals.
How similar studies have gone: Other research has successfully identified new drug targets in similar parasitic infections, suggesting that this approach has potential for success.
Where this research is happening
-
Acheminall Corporation
Naperville, United States Active
Researchers
- Principal investigator: Petukhov, Pavel — Acheminall Corporation
- Study coordinator: Petukhov, Pavel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.